BioSpectrum Asia: Beyond Self-Reliance: BioJapan Turns 40 by Asking Japan to Orchestrate
BioSpectrum Asia’s Day 1 report from BioJapan 2026 highlights the AN Venture Partners investment forum. Ken Horne and Incubate Executive Director John Stanford opened the session by covering U.S. drug pricing policy, FDA changes, China-related investment restrictions and Japan’s drug pricing system. U.S. investors Marian Nakada, Michael Gutbrod of Santé Ventures and Josh Resnick of RA Capital Management then discussed how geopolitics shapes their allocation decisions and what it would take to expand investment in Japanese science.

Comments